Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IOP Injection for Liver MRI in Healthy Subjects
NCT03399214Phase 1Completed
- Sponsor
- MegaPro Biomedical
- Start
- Apr 2018
- Primary completion
- May 2018
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MPB-1514 in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by MegaPro Biomedical. Primary endpoint: The Change of MRI SI (%) in vessels, liver, and spleen at Day 1. Started Apr 2018; status: completed.
02
Drugs
MPB-1514
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03399214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399214.